Salvage	salvage	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
nelarabine	nelarabine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
relapsed/refractory	relapsed/refractory	O	O	O	O
paediatric	paediatric	O	O	O	O
T-cell	t-cell	O	O	O	O
lymphoblastic	lymphoblastic	O	O	O	O
leukaemia	leukaemia	O	O	OTHERS	I
and	and	O	O	O	O
lymphoma	lymphoma	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
5	5	O	O	O	O
d	d	O	O	O	O
of	of	O	O	O	O
nelarabine	nelarabine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
AraG	arag	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
with	with	O	O	O	O
5	5	O	O	O	O
d	d	O	O	O	O
of	of	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
VP	vp	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
CPM	cpm	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
prophylactic	prophylactic	O	O	O	O
intrathecal	intrathecal	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
was	was	O	O	O	O
used	used	O	O	O	O
as	as	O	O	O	O
salvage	salvage	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
seven	seven	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
refractory	refractory	O	O	O	O
or	or	O	O	O	O
relapsed	relapsed	O	O	O	O
T-cell	t-cell	O	O	O	O
leukaemia	leukaemia	O	O	OTHERS	I
or	or	O	O	O	O
lymphoma	lymphoma	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
attributable	attributable	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
AraG	arag	CHEMICALS	O	OTHERS	I
included	included	O	O	O	O
Grade	grade	O	O	O	O
2	2	O	O	O	O
and	and	O	O	O	O
3	3	O	O	O	O
sensory	sensory	O	O	O	O
and	and	O	O	O	O
motor	motor	O	O	OTHERS	I
neuropathy	neuropathy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
musculoskeletal	musculoskeletal	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Haematological	haematological	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
greater	greater	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
than	than	O	O	O	O
AraG	arag	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
median	median	O	O	O	O
time	time	O	O	O	O
to	to	O	O	O	O
neutrophil	neutrophil	O	O	O	O
and	and	O	O	O	O
platelet	platelet	O	O	O	O
recovery	recovery	O	O	O	O
was	was	O	O	O	O
consistent	consistent	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
salvage	salvage	O	O	O	O
therapies	therapies	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
some	some	O	O	O	O
response	response	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
combined	combined	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
five	five	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
seven	seven	O	O	O	O
went	went	O	O	O	O
into	into	O	O	O	O
complete	complete	O	O	O	O
remission	remission	O	O	O	O
after	after	O	O	O	O
one	one	O	O	O	O
or	or	O	O	O	O
two	two	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
AraG/VP/CPM	arag/vp/cpm	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
experience	experience	O	O	O	O
supports	supports	O	O	O	O
the	the	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
giving	giving	O	O	O	O
AraG	arag	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
salvage	salvage	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
synchrony	synchrony	O	O	O	O
with	with	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
neurological	neurological	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
must	must	O	O	O	O
be	be	O	O	O	O
closely	closely	O	O	O	O
monitored	monitored	O	O	O	O
.	.	O	O	O	O

